The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enrichment of circulating helper-T (Th) and unswitched memory-B (NSwM-B) cell populations and responsiveness to immune checkpoint blockade (ICB) in microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) colorectal cancer (CRC).
 
Sebastian Meltzer
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - AstraZeneca (Inst); BMS Norway (Inst); Illumina (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
Sebastian Franco Ulloa
No Relationships to Disclose
 
Tonje Bjørnetrø
No Relationships to Disclose
 
Hanne M Hamre
No Relationships to Disclose
 
Fatemeh Kaveh
No Relationships to Disclose
 
Sébastien Wälchli
Patents, Royalties, Other Intellectual Property - US11155786
 
Kjersti Flatmark
No Relationships to Disclose
 
Else Marit Inderberg
Stock and Other Ownership Interests - Ultimovacs
Patents, Royalties, Other Intellectual Property - Patent related to cancer vaccine, US9657068B2 The patent has been bought by Ultimovacs ASA; Patent WO2016116601A1 licensed to Zelluna Immunotherapy AS by TTO of Oslo University Hospital, Inven2
 
Anne Hansen Ree
Research Funding - Bristol-Mers Squibb (Inst)